ArticleStem cell research & therapy2025
Routinely collected data: a path to assess safety of human mesenchymal stromal cell transplantation in randomized controlled trials.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human mesenchymal stromal cells (hMSCs) are currently at the center of interest in many randomized and non-randomized clinical trials. According to the data, the number of trials on hMSCs has increased rapidly over time. However, the safety of this treatment, despite some available evidence, remains questionable. Routinely collected data (RCD) has become a helpful approach for gathering clinical data, especially in clinical trials. This method of data collection has helped investigators overcome the limitations of randomized controlled trials (RCTs), such as ensuring long-term follow-ups. Herein, the potential role of RCD in investigating the safety of hMSCs in RCTs, particularly concerns about their possible pro-tumorigenic potential, is discussed. The patterns of recent trials in this field suggest high feasibility and the potential for using RCD for this purpose.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.